DrugId:  1
1. Name:  Beta vulgaris pollen
2. Groups:  Approved
3. Description:  Beta vulgaris pollen is the pollen of the Beta vulgaris plant. Beta vulgaris pollen is mainly used in allergenic testing.
4. Indication:  Not Available
DrugId:  2
1. Name:  Artemisia vulgaris pollen
2. Groups:  Approved
3. Description:  Artemisia vulgaris pollen is the pollen of the Artemisia vulgaris plant. Artemisia vulgaris pollen is mainly used in allergenic testing.
4. Indication:  Not Available
DrugId:  3
1. Name:  Sifalimumab
2. Groups:  Investigational
3. Description:  Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity. Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.
4. Indication:  Not Available
DrugId:  4
1. Name:  Canis lupus familiaris dander
2. Groups:  Approved
3. Description:  Canis lupus familiaris dander is the dander of Canis lupus familiaris. Canis lupus familiaris dander is used in allergenic testing.
4. Indication:  Not Available
DrugId:  5
1. Name:  Rontalizumab
2. Groups:  Investigational
3. Description:  Rontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus.
4. Indication:  Not Available
DrugId:  6
1. Name:  Atacicept
2. Groups:  Investigational
3. Description:  Atacicept is a recombinant fusion protein combined with the extracellular ligand binding portion of TACI.
4. Indication:  Investigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).
DrugId:  7
1. Name:  Ruplizumab
2. Groups:  Investigational
3. Description:  Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.
4. Indication:  Investigated for use/treatment in thrombocytopenia, systemic lupus erythematosus, transplant (rejection), blood (blood forming organ disorders, unspecified), and multiple sclerosis.
DrugId:  8
1. Name:  Vespula vulgaris venom protein
2. Groups:  Approved
3. Description:  Vespula vulgaris venom protein is an extract of Vespula vulgaris venom. Vespula vulgaris venom protein is used in allergenic testing.
4. Indication:  Not Available
DrugId:  9
1. Name:  Forigerimod
2. Groups:  Investigational
3. Description:  Forigerimod is under investigation for the treatment of Lupus Erythematosus, Systemic.
4. Indication:  Not Available
DrugId:  10
1. Name:  Blisibimod
2. Groups:  Investigational
3. Description:  Blisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis.
4. Indication:  Not Available
DrugId:  11
1. Name:  Milatuzumab
2. Groups:  Investigational
3. Description:  Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
4. Indication:  Not Available
DrugId:  12
1. Name:  Tabalumab
2. Groups:  Investigational
3. Description:  Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
4. Indication:  Not Available
DrugId:  13
1. Name:  PMI-001
2. Groups:  Investigational
3. Description:  PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc. It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis, lupus erythematosus and psoriasis.
4. Indication:  Investigated for use/treatment in rheumatoid arthritis.
DrugId:  14
1. Name:  Epratuzumab
2. Groups:  Investigational
3. Description:  Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monotclonal antibody, LL2 (EPB-2). Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE).
4. Indication:  Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
DrugId:  15
1. Name:  Gevokizumab
2. Groups:  Investigational
3. Description:  Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.
4. Indication:  Not Available
DrugId:  16
1. Name:  Abetimus
2. Groups:  Investigational
3. Description:  Abetimus is an immunosuppressant developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.
4. Indication:  Investigated for use/treatment in kidney disease and systemic lupus erythematosus.
DrugId:  17
1. Name:  AN0128
2. Groups:  Investigational
3. Description:  AN0128 is a novel compound that contains a boron atom within a borinic acid complex. AN0128 has broad spectrum activity against a wide variety of Gram positivebacteria, including many that are known skin colonizers. Of particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibioticresistance of P. acnes to standard antibiotics necessitates the development of new treatment agents. AN0128 is a good candidate for a topical antibiotic and is currently being developed by Anacor as a novel therapeutic for acne and atopic dermatitis.
4. Indication:  Investigated for use/treatment in acne, atopic dermatitis, pediatric indications, and psoriasis and psoriatic disorders.
DrugId:  18
1. Name:  Trifarotene
2. Groups:  Investigational
3. Description:  Trifarotene has been used in trials studying the treatment of Acne Vulgaris.
4. Indication:  Not Available
DrugId:  19
1. Name:  Fluasterone
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in psoriasis and psoriatic disorders, hyperlipidemia, metabolic disease, cancer/tumors (unspecified), and obesity.
DrugId:  20
1. Name:  Cantharidin
2. Groups:  Approved, Investigational
3. Description:  Cantharidin has been investigated for the treatment of Verruca Vulgaris and Molluscum Contagiosum.
4. Indication:  Not Available
DrugId:  21
1. Name:  Olumacostat glasaretil
2. Groups:  Investigational
3. Description:  Olumacostat glasaretil has been used in trials studying the treatment of Acne Vulgaris.
4. Indication:  Not Available
DrugId:  22
1. Name:  Cenerimod
2. Groups:  Investigational
3. Description:  Cenerimod has been used in trials studying the treatment of Systemic Lupus Erythematosus.
4. Indication:  Not Available
DrugId:  23
1. Name:  PF-05175157
2. Groups:  Investigational
3. Description:  PF-05175157 has been used in trials studying the basic science and treatment of Acne Vulgaris, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus Type 2, and Diabetes Mellitus, Type 2, among others.
4. Indication:  Not Available
DrugId:  24
1. Name:  Brodalumab
2. Groups:  Approved, Investigational
3. Description:  Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
4. Indication:  Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. 
DrugId:  25
1. Name:  CR002
2. Groups:  Investigational
3. Description:  CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. This is a novel therapeutic approach to treat kidney inflammation.
4. Indication:  Investigated for use/treatment in nephropathy.
